Insider buying last 90 days
No open-market insider purchases were filed for IMNM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IMNM insider filing, plotted on the chart in Gekko.Open IMNM in Gekko
NASDAQ: IMNM
Immunome (IMNM) Stock Analysis & Forecast
Oct 12 close
$19.15−0.40 (−2.0%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on Immunome's oncology pipeline progress and a licensing cleanup. The FDA cleared the IND for IM-1340, an antibody-drug conjugate targeting advanced solid tumors, marking the company's fifth clinical program, with a Phase 1 study expected in Q4 2026. Separately, Immunome entered a licensing agreement with Bristol, paying $20 million and issuing shares to eliminate payment obligations and acquire varegacestat patent rights, a move Stifel addressed by maintaining a Hold rating and a $24.00 price target. Immunome also amended its license agreement with AbbVie to clarify exclusive target definitions, and reported inducement grants to ten new employees.
Immunome shares closed at $19.15, down 2% on the day, sitting between the 50-day average of $24.87 and the 200-day average of $22.70, with one-month returns of -22.4% and six-month returns of -15.3%. The GekkoIndex reads 71.5, placing the stock in the Buying zone. Price sits 18.3% below Gekko Fair Value of $23.43.
Earnings are scheduled for 5 November 2026, 24 days away, falling inside a typical 20-trading-day holding window; the last report showed an EPS miss of -$0.65 versus a -$0.51 estimate, with a 9% reaction. Seasonality from this point in the calendar has averaged an 8% gain over the next 20 trading days across 5 years, with gains in 4 of them. No insider, Congress, or unusual options activity appears in the recent windows. Analyst consensus stands at 11 buy ratings and 1 hold among 12 firms, with a consensus target of $35.20.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Immunome price vs fair value
Close $19.15200-day averageGekko Fair Value $23.43
Immunome quick facts
- Market cap
- $1.83B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.52
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.56
- Volume
- 835,700 avg 1.55M
- 1-year return
- +34.0%
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±14.5%
- 50-day average
- $24.87
- 200-day average
- $22.70
- Next earnings
- Nov 5
- Shares outstanding
- 118.0M
Immunome swing-trade checklist
Immunome scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $19.15 sits between the 50-day ($24.87) and 200-day ($22.70) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.5, Buying
Reading 71.5 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
18.3% below
Price is 18.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+8.0% on average
From this point in the calendar, the next 20 trading days averaged +8% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Immunome stock chart and price history
Immunome closed at $19.15 on Oct 12, 2026, +34.0% over the past year, inside a 52-week range of $13.49 to $30.06.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −22.4%
- 3 months
- −15.2%
- 6 months
- −15.3%
- 1 year
- +34.0%
The full IMNM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IMNM in Gekko
Follow Immunome through every session
Put IMNM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IMNM in GekkoFree for 7 days. No credit card required.
About Immunome
Immunome works in biotechnology, focused on finding, building, manufacturing and bringing to market antibody-drug conjugates and other treatments for cancer within the United States. Its most advanced program is Varegacestat, a gamma secretase inhibitor now in Phase 3 testing for desmoid tumors, alongside IM-1021, an antibody-drug conjugate targeting the ROR1 receptor that is in Phase 1 trials.
Beyond these clinical-stage efforts, the company maintains a pipeline of earlier preclinical candidates. These include IM-3050, a radioligand therapy aimed at fibroblast activation protein, as well as several solid tumor antibody-drug conjugates under development, namely IM-1617, IM-1340 and IM-1335.
Immunome was incorporated in 2006 and operates out of Bothell, Washington. Its shares trade on the NASDAQ under the ticker IMNM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- immunome.com
Immunome GekkoIndex: the smart money zone
Immunome’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.5, in the Buying zone, up 1.4 points over five sessions.
71.5Buying
Up 1.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 55 | +3.9% | +17.1% | ||
| Accumulation | 209 | −0.1% | −0.7% | ||
| Neutral | 387 | +0.9% | +1.9% | ||
| Distribution | 29 | −1.0% | +5.6% | ||
| Selling | 2 | Too few readings yet | |||
Average IMNM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the IMNM price, zone by zone.Track IMNM in Gekko
Is Immunome stock overvalued? Gekko Fair Value
Immunome trades 18.3% below Gekko Fair Value of $23.43, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Immunome shares are worth, recalculated every trading day.
$23.43
Gekko Fair Value, Oct 10, 2026
18.3% Undervalued
At the end of Aug 2026 the price was 22.7% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IMNM in Gekko
Immunome insider and Congress trading
No open-market insider purchases were filed for Immunome, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IMNM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IMNM, plotted on the chart in Gekko.Open IMNM in Gekko
Buybacks
Immunome has been buying back its own shares.
- Bought back, year ended Dec 31, 2019
- $35K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold IMNM.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Immunome earnings: next date and track record
Immunome reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$0.60
- Revenue estimate
- $167K
2 of 8reports beat the EPS estimate
±5.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.65 est −$0.51 | — est $167K | +9.0% |
| May 12, 2026 | $0.00 est −$0.59 | — est $222K | −3.5% |
| Mar 3, 2026 | −$0.76 est −$0.58 | — est $876K | +1.4% |
| Nov 6, 2025 | −$0.65 est −$0.57 | — est $850K | −0.7% |
| Aug 6, 2025 | −$0.50 est −$0.52 | $4.02M est $833K | −9.0% |
| Mar 19, 2025 | −$0.84 est −$0.68 | $2.74M est $3.15M | +3.6% |
| Nov 13, 2024 | −$0.78 est −$0.56 | $2.91M est $3.16M | −10.8% |
| Aug 12, 2024 | −$0.49 est −$0.39 | $2.36M est $2.55M | +4.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Immunome stock forecast and analyst price targets
Analysts’ average 12-month price target for Immunome is $35.20, +83.8% from the last close, from 12 firms rating the stock in the last 90 days.
$35.20consensus 12-month target, +83.8% from the last close
Now $19.15Avg $35.20
Low $24High $40
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 6 | Stifel Nicolaus | $24 | +25.3% |
| Oct 5 | LifeSci Capital | $40 | +108.9% |
| Oct 1 | Barclays | $36 | +88.0% |
| Oct 1 | Stifel Nicolaus | $24 | +25.3% |
| Sep 30 | Stifel Nicolaus | $24 | +25.3% |
+17.1%average 20-day move after past Buying readings
+8.0%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Immunome seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Immunome averaged +8.0% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +6.4% | 5 of 5 |
| Next 10 trading days | +6.5% | 3 of 5 |
| Next 15 trading days | +10.6% | 3 of 5 |
| Next 20 trading days | +8.0% | 4 of 5 |
| Next 30 trading days | −6.1% | 2 of 5 |
For scale, IMNM’s typical 20-trading-day move in either direction is about 14.5%.
Immunome market cap and key statistics
Immunome’s market cap is $1.83B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.83B
- EPS, TTM
- −$2.52
- Gekko Fair Value
- $23.43
Trading
- Volume
- 835,700
- Avg volume, 20 days
- 1.55M
- 52-week high
- $30.06
- 52-week low
- $13.49
- Shares outstanding
- 118.0M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -64%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.56
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±14.5%
Immunome stock news this week
Coverage of Immunome this week reads positive: 6 positive, 1 neutral and 0 negative headlines.
- Does FDA Trial Clearance Change The Bull Case For Immunome (IMNM)?Simply Wall Street, Oct 9
- Immunome (IMNM) Wins FDA IND Clearance, Is It Still 47% Below Fair Value?Simply Wall Street, Oct 7
- Immunome stock holds at Stifel as Bristol deal cleans up licenseInvesting.com, Oct 7
- Immunome stock advances clinical pipeline after FDA clearanceAD HOC NEWS, Oct 7
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance, Oct 6
- Immunome - Enters Amendment No. 4 to LicenseMoomoo, Oct 5
Immunome peers
Immunome’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Immunome stock FAQ
What is Immunome’s market cap?
Immunome’s market cap is $1.83B at the Oct 12, 2026 close of $19.15, with 118.0M shares outstanding.
What is the Immunome stock forecast?
The consensus analyst 12-month price target for Immunome is $35.20, +83.8% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Immunome stock overvalued or undervalued?
On Gekko’s estimate Immunome is undervalued: the Oct 12, 2026 close of $19.15 is 18.3% below Gekko Fair Value of $23.43. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Immunome report earnings next?
Immunome is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$0.60 per share on revenue of $167K. Immunome beat the earnings estimate in 2 of its last 8 reports, moving 5.3% on average across the report.
What is Immunome’s 52-week high and low?
Immunome’s 52-week high is $30.06 and its 52-week low is $13.49; it closed at $19.15 on Oct 12, 2026, +34.0% over the past year. Over the last five years the shares peaked at $30.96 on Mar 7, 2024.
Is Immunome stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Immunome the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.